Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience
Heplisav-B, a hepatitis B virus (HBV) vaccine with an immunostimulatory adjuvant, was FDA approved in 2017 for adults ≥18 years. In randomized controlled trials, Heplisav-B demonstrated seroprotection rates (SPR) of 90%-95% versus 65%-80% for Engerix-B. No studies have included people with HIV (PWH)...
Gespeichert in:
| Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1999) 2021-04, Vol.86 (4), p.445-449 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 449 |
|---|---|
| container_issue | 4 |
| container_start_page | 445 |
| container_title | Journal of acquired immune deficiency syndromes (1999) |
| container_volume | 86 |
| creator | Schnittman, Samuel R. Zepf, Roland Cocohoba, Jennifer Sears, David |
| description | Heplisav-B, a hepatitis B virus (HBV) vaccine with an immunostimulatory adjuvant, was FDA approved in 2017 for adults ≥18 years. In randomized controlled trials, Heplisav-B demonstrated seroprotection rates (SPR) of 90%-95% versus 65%-80% for Engerix-B. No studies have included people with HIV (PWH), and the SPR and its predictors in this population are unknown.
Quaternary care center HIV clinic.
This retrospective cohort study evaluated PWH aged ≥18 years without current HBV seroprotection (anti-HBV surface antibody level [anti-HBs] |
| doi_str_mv | 10.1097/QAI.0000000000002573 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2461399588</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2461399588</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3521-bb86f2744c45d70110796707b2aa52aa40c0eff21fa4b945e5c4cf6a1cc0583a3</originalsourceid><addsrcrecordid>eNpdkEtPHDEMgCNUxPsfoCrHXkLjxJkHt2VF2ZWQypvjKBM87NDszDSZhfLvGwSUCkuWfbA_Wx9j-yAPQJb59_PJ_ED-F8rkeo1tQYko8qLAL6k3yggEbTbZdowPUkKGWG6wTa2hzIzRW-zmKLTU8Asa-jAe8hkNvo32URzxSwr9EPqR3Nj2HW87fkb94InftuOCz-Y3h3zCL9vu3pOYUjdS4Md_Bkq4ztEuW2-sj7T3VnfY9Y_jq-lMnP48mU8np8Jpo0DUdZE1Kkd0aO5yCSDzMstlXitrTUqUTlLTKGgs1iUaMg5dk1lwTppCW73Dvr1y06e_VxTHatlGR97bjvpVrBRmoMvSFEUaxddRF_oYAzXVENqlDc8VyOrFaJWMVp-NprWvbxdW9ZLu_i29K_zgPvU-SYi__OqJQrUg68dF4oHKtEahpAKJEqRIZAD9F1xMfv4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2461399588</pqid></control><display><type>article</type><title>Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Free E- Journals</source><creator>Schnittman, Samuel R. ; Zepf, Roland ; Cocohoba, Jennifer ; Sears, David</creator><creatorcontrib>Schnittman, Samuel R. ; Zepf, Roland ; Cocohoba, Jennifer ; Sears, David</creatorcontrib><description>Heplisav-B, a hepatitis B virus (HBV) vaccine with an immunostimulatory adjuvant, was FDA approved in 2017 for adults ≥18 years. In randomized controlled trials, Heplisav-B demonstrated seroprotection rates (SPR) of 90%-95% versus 65%-80% for Engerix-B. No studies have included people with HIV (PWH), and the SPR and its predictors in this population are unknown.
Quaternary care center HIV clinic.
This retrospective cohort study evaluated PWH aged ≥18 years without current HBV seroprotection (anti-HBV surface antibody level [anti-HBs] <10 mIU/mL) who were administered Heplisav-B. Patients without post-immunization titers were excluded. The primary outcome was the SPR, the proportion of participants with HBV seroprotection at any point after the first vaccination.
Among 64 PWH included, median time to anti-HBs measurement after vaccination was 13 weeks. The median age was 58 years, 81% were men, and 95% had a viral load <200. The SPR was 81% in the entire cohort (and 86% in those without significant non-HIV immunosuppression), 79% in those with no prior HBV vaccination and no anti-HBc positivity, and 84% in those with prior vaccine nonresponse. Lower current and nadir CD4+ counts were associated with progressively lower seroprotection.
In the first single-center retrospective study of Heplisav-B in PWH, the SPR compared favorably with the SPR seen among PWH from prior HBV vaccines across key subgroups. Given these findings, Heplisav-B should be considered for expanded use for HBV vaccination in PWH. Further research on the effectiveness of a repeat vaccination series or higher dosing in nonresponders is needed.</description><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 1944-7884</identifier><identifier>DOI: 10.1097/QAI.0000000000002573</identifier><identifier>PMID: 33196553</identifier><language>eng</language><publisher>United States: JAIDS Journal of Acquired Immune Deficiency Syndromes</publisher><subject>Adjuvants, Immunologic ; Adolescent ; Adult ; Aged ; CD4 Lymphocyte Count ; Cohort Studies ; Female ; Hepatitis B - prevention & control ; Hepatitis B Vaccines - immunology ; HIV Infections - complications ; HIV-1 ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Viral Load ; Young Adult</subject><ispartof>Journal of acquired immune deficiency syndromes (1999), 2021-04, Vol.86 (4), p.445-449</ispartof><rights>JAIDS Journal of Acquired Immune Deficiency Syndromes</rights><rights>Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3521-bb86f2744c45d70110796707b2aa52aa40c0eff21fa4b945e5c4cf6a1cc0583a3</citedby><cites>FETCH-LOGICAL-c3521-bb86f2744c45d70110796707b2aa52aa40c0eff21fa4b945e5c4cf6a1cc0583a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf><![CDATA[$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&PDF=y&D=ovft&AN=00126334-202104010-00011$$EPDF$$P50$$Gwolterskluwer$$H]]></linktopdf><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00126334-202104010-00011$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,780,784,4609,27924,27925,64666,65461</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33196553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schnittman, Samuel R.</creatorcontrib><creatorcontrib>Zepf, Roland</creatorcontrib><creatorcontrib>Cocohoba, Jennifer</creatorcontrib><creatorcontrib>Sears, David</creatorcontrib><title>Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience</title><title>Journal of acquired immune deficiency syndromes (1999)</title><addtitle>J Acquir Immune Defic Syndr</addtitle><description>Heplisav-B, a hepatitis B virus (HBV) vaccine with an immunostimulatory adjuvant, was FDA approved in 2017 for adults ≥18 years. In randomized controlled trials, Heplisav-B demonstrated seroprotection rates (SPR) of 90%-95% versus 65%-80% for Engerix-B. No studies have included people with HIV (PWH), and the SPR and its predictors in this population are unknown.
Quaternary care center HIV clinic.
This retrospective cohort study evaluated PWH aged ≥18 years without current HBV seroprotection (anti-HBV surface antibody level [anti-HBs] <10 mIU/mL) who were administered Heplisav-B. Patients without post-immunization titers were excluded. The primary outcome was the SPR, the proportion of participants with HBV seroprotection at any point after the first vaccination.
Among 64 PWH included, median time to anti-HBs measurement after vaccination was 13 weeks. The median age was 58 years, 81% were men, and 95% had a viral load <200. The SPR was 81% in the entire cohort (and 86% in those without significant non-HIV immunosuppression), 79% in those with no prior HBV vaccination and no anti-HBc positivity, and 84% in those with prior vaccine nonresponse. Lower current and nadir CD4+ counts were associated with progressively lower seroprotection.
In the first single-center retrospective study of Heplisav-B in PWH, the SPR compared favorably with the SPR seen among PWH from prior HBV vaccines across key subgroups. Given these findings, Heplisav-B should be considered for expanded use for HBV vaccination in PWH. Further research on the effectiveness of a repeat vaccination series or higher dosing in nonresponders is needed.</description><subject>Adjuvants, Immunologic</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>CD4 Lymphocyte Count</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Hepatitis B - prevention & control</subject><subject>Hepatitis B Vaccines - immunology</subject><subject>HIV Infections - complications</subject><subject>HIV-1</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Viral Load</subject><subject>Young Adult</subject><issn>1525-4135</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkEtPHDEMgCNUxPsfoCrHXkLjxJkHt2VF2ZWQypvjKBM87NDszDSZhfLvGwSUCkuWfbA_Wx9j-yAPQJb59_PJ_ED-F8rkeo1tQYko8qLAL6k3yggEbTbZdowPUkKGWG6wTa2hzIzRW-zmKLTU8Asa-jAe8hkNvo32URzxSwr9EPqR3Nj2HW87fkb94InftuOCz-Y3h3zCL9vu3pOYUjdS4Md_Bkq4ztEuW2-sj7T3VnfY9Y_jq-lMnP48mU8np8Jpo0DUdZE1Kkd0aO5yCSDzMstlXitrTUqUTlLTKGgs1iUaMg5dk1lwTppCW73Dvr1y06e_VxTHatlGR97bjvpVrBRmoMvSFEUaxddRF_oYAzXVENqlDc8VyOrFaJWMVp-NprWvbxdW9ZLu_i29K_zgPvU-SYi__OqJQrUg68dF4oHKtEahpAKJEqRIZAD9F1xMfv4</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Schnittman, Samuel R.</creator><creator>Zepf, Roland</creator><creator>Cocohoba, Jennifer</creator><creator>Sears, David</creator><general>JAIDS Journal of Acquired Immune Deficiency Syndromes</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210401</creationdate><title>Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience</title><author>Schnittman, Samuel R. ; Zepf, Roland ; Cocohoba, Jennifer ; Sears, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3521-bb86f2744c45d70110796707b2aa52aa40c0eff21fa4b945e5c4cf6a1cc0583a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adjuvants, Immunologic</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>CD4 Lymphocyte Count</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Hepatitis B - prevention & control</topic><topic>Hepatitis B Vaccines - immunology</topic><topic>HIV Infections - complications</topic><topic>HIV-1</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Viral Load</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schnittman, Samuel R.</creatorcontrib><creatorcontrib>Zepf, Roland</creatorcontrib><creatorcontrib>Cocohoba, Jennifer</creatorcontrib><creatorcontrib>Sears, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schnittman, Samuel R.</au><au>Zepf, Roland</au><au>Cocohoba, Jennifer</au><au>Sears, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience</atitle><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle><addtitle>J Acquir Immune Defic Syndr</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>86</volume><issue>4</issue><spage>445</spage><epage>449</epage><pages>445-449</pages><issn>1525-4135</issn><eissn>1944-7884</eissn><abstract>Heplisav-B, a hepatitis B virus (HBV) vaccine with an immunostimulatory adjuvant, was FDA approved in 2017 for adults ≥18 years. In randomized controlled trials, Heplisav-B demonstrated seroprotection rates (SPR) of 90%-95% versus 65%-80% for Engerix-B. No studies have included people with HIV (PWH), and the SPR and its predictors in this population are unknown.
Quaternary care center HIV clinic.
This retrospective cohort study evaluated PWH aged ≥18 years without current HBV seroprotection (anti-HBV surface antibody level [anti-HBs] <10 mIU/mL) who were administered Heplisav-B. Patients without post-immunization titers were excluded. The primary outcome was the SPR, the proportion of participants with HBV seroprotection at any point after the first vaccination.
Among 64 PWH included, median time to anti-HBs measurement after vaccination was 13 weeks. The median age was 58 years, 81% were men, and 95% had a viral load <200. The SPR was 81% in the entire cohort (and 86% in those without significant non-HIV immunosuppression), 79% in those with no prior HBV vaccination and no anti-HBc positivity, and 84% in those with prior vaccine nonresponse. Lower current and nadir CD4+ counts were associated with progressively lower seroprotection.
In the first single-center retrospective study of Heplisav-B in PWH, the SPR compared favorably with the SPR seen among PWH from prior HBV vaccines across key subgroups. Given these findings, Heplisav-B should be considered for expanded use for HBV vaccination in PWH. Further research on the effectiveness of a repeat vaccination series or higher dosing in nonresponders is needed.</abstract><cop>United States</cop><pub>JAIDS Journal of Acquired Immune Deficiency Syndromes</pub><pmid>33196553</pmid><doi>10.1097/QAI.0000000000002573</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-4135 |
| ispartof | Journal of acquired immune deficiency syndromes (1999), 2021-04, Vol.86 (4), p.445-449 |
| issn | 1525-4135 1944-7884 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2461399588 |
| source | MEDLINE; Journals@Ovid LWW Legacy Archive; Free E- Journals |
| subjects | Adjuvants, Immunologic Adolescent Adult Aged CD4 Lymphocyte Count Cohort Studies Female Hepatitis B - prevention & control Hepatitis B Vaccines - immunology HIV Infections - complications HIV-1 Humans Male Middle Aged Retrospective Studies Viral Load Young Adult |
| title | Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A36%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brief%20Report:%20Heplisav-B%20Seroprotection%20in%20People%20With%20HIV:%20A%20Single-Center%20Experience&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&rft.au=Schnittman,%20Samuel%20R.&rft.date=2021-04-01&rft.volume=86&rft.issue=4&rft.spage=445&rft.epage=449&rft.pages=445-449&rft.issn=1525-4135&rft.eissn=1944-7884&rft_id=info:doi/10.1097/QAI.0000000000002573&rft_dat=%3Cproquest_cross%3E2461399588%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2461399588&rft_id=info:pmid/33196553&rfr_iscdi=true |